Literature DB >> 35260950

Disparities in psychological distress and access to mental health services among immigrants with rheumatologic disease.

Troy B Amen1, Tyler J Chavez2, Edward Christopher Dee3, Nathan H Varady4, Jasper Seth Yao5, Joseph Alexander Paguio5, Antonia F Chen6.   

Abstract

INTRODUCTION: Patients with rheumatologic disease experience higher rates of comorbid mental health diseases than those without. Although mental health services (MHS) can improve musculoskeletal functional outcomes, access to MHS has been limited among vulnerable populations in the United States (US). The purpose of this study was to investigate contemporary patterns of severe psychological distress and receipt of MHS among immigrant populations with rheumatologic disease in the US.
METHODS: The National Health Interview Survey was queried for patients with rheumatologic disease from 2009 to 2018. Patient demographics, severe psychological distress, and receipt of MHS were collected and/or calculated. Multivariable logistic regressions assessed for factors associated with decreased receipt of MHS and severe psychological distress.
RESULTS: Immigrant patients with rheumatologic disease had higher rates of severe psychological distress than US-born patients (7.7% vs. 6.5%, p < 0.001), but were less likely to access MHS (8.3% vs. 11.0%, p < 0.001). Among immigrant patients, factors associated with lower MHS receipt included being Black (AOR 0.50, 95% CI 0.32-0.77, p = 0.002), Hispanic (AOR 0.80, 95% CI 0.30-1.00, p = 0.050), Asian (AOR 0.44, 95% CI 0.31-0.63, p < 0.001), older (p < 0.001), uninsured (p < 0.001), and having self-reported poor health (p < 0.001). DISCUSSION: Immigrant patients with rheumatologic disease in the US had higher rates of severe psychological distress yet were less likely to receive MHS compared to US-born patients. Immigrants with rheumatologic illness were less likely to receive MHS if they were male, Black, Hispanic, Asian, older, lower income, or uninsured. This lack of MHS receipt may contribute to disparities in functional outcomes seen in immigrant minorities with musculoskeletal disease. Key Points • Immigrant patients with rheumatologic disease in the US had higher rates of severe psychological distress yet were less likely to receive MHS compared to US-born patients between 2009 and 2018 • Immigrants with rheumatologic illness were less likely to receive MHS if they were Black, Hispanic, Asian, older, lower income, or uninsured • Future efforts to carefully screen for mental health diseases in these vulnerable patient populations should be made while exploring patient-specific cultural considerations of MHS receipt.
© 2022. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Disparities in Immigrant health; Mental health services; Rheumatologic disease

Mesh:

Year:  2022        PMID: 35260950     DOI: 10.1007/s10067-022-06074-6

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

1.  Screening for serious mental illness in the general population.

Authors:  Ronald C Kessler; Peggy R Barker; Lisa J Colpe; Joan F Epstein; Joseph C Gfroerer; Eva Hiripi; Mary J Howes; Sharon-Lise T Normand; Ronald W Manderscheid; Ellen E Walters; Alan M Zaslavsky
Journal:  Arch Gen Psychiatry       Date:  2003-02

2.  Depression, anxiety, and quality of life in a large cohort of patients with rheumatic diseases: common, yet undertreated.

Authors:  Panagiota Anyfanti; Eleni Gavriilaki; Athina Pyrpasopoulou; George Triantafyllou; Areti Triantafyllou; Sofia Chatzimichailidou; Eugenia Gkaliagkousi; Spyros Aslanidis; Stella Douma
Journal:  Clin Rheumatol       Date:  2014-05-25       Impact factor: 2.980

3.  Challenges for immigrant health in the USA-the road to crisis.

Authors:  Dhruv Khullar; Dave A Chokshi
Journal:  Lancet       Date:  2019-04-10       Impact factor: 79.321

4.  Screening for serious mental illness in the general population with the K6 screening scale: results from the WHO World Mental Health (WMH) survey initiative.

Authors:  Ronald C Kessler; Jennifer Greif Green; Michael J Gruber; Nancy A Sampson; Evelyn Bromet; Marius Cuitan; Toshi A Furukawa; Oye Gureje; Hristo Hinkov; Chi-Yi Hu; Carmen Lara; Sing Lee; Zeina Mneimneh; Landon Myer; Mark Oakley-Browne; Jose Posada-Villa; Rajesh Sagar; Maria Carmen Viana; Alan M Zaslavsky
Journal:  Int J Methods Psychiatr Res       Date:  2010-06       Impact factor: 4.035

5.  Subsequent risk of hospitalization for neuropsychiatric disorders in patients with rheumatic diseases: a nationwide study from Sweden.

Authors:  Kristina Sundquist; Xinjun Li; Kari Hemminki; Jan Sundquist
Journal:  Arch Gen Psychiatry       Date:  2008-05

6.  Racial and ethnic differences in medication use among beneficiaries of social security disability insurance with rheumatoid arthritis.

Authors:  Iris Navarro-Millán; Mangala Rajan; Geyanne E Lui; Lisa M Kern; Laura C Pinheiro; Monika M Safford; Sebastian E Sattui; Jeffrey R Curtis
Journal:  Semin Arthritis Rheum       Date:  2020-07-23       Impact factor: 5.532

Review 7.  Barriers to health care for undocumented immigrants: a literature review.

Authors:  Karen Hacker; Maria Anies; Barbara L Folb; Leah Zallman
Journal:  Risk Manag Healthc Policy       Date:  2015-10-30

Review 8.  Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review.

Authors:  May N Lwin; Lina Serhal; Christopher Holroyd; Christopher J Edwards
Journal:  Rheumatol Ther       Date:  2020-06-13

9.  Symptoms of Anxiety and Depression Among Adults with Arthritis - United States, 2015-2017.

Authors:  Dana Guglielmo; Jennifer M Hootman; Michael A Boring; Louise B Murphy; Kristina A Theis; Janet B Croft; Kamil E Barbour; Patricia P Katz; Charles G Helmick
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-10-05       Impact factor: 17.586

Review 10.  The Role of Inflammation in Depression and Fatigue.

Authors:  Chieh-Hsin Lee; Fabrizio Giuliani
Journal:  Front Immunol       Date:  2019-07-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.